(187 Total References)
Depression and Bipolar Support Alliance (DBSA) Advisory Board | CCHR International
The members are: Mark S Bauer, Charles L. Bowden (with financial ties to Abbot, GSK, Janssen), Joseph Calabrese (Abbot, GSK, Janssen), Alan Gelenberg (GSK), Michael E. Thase (GSK, Janssen), Gary S Sachs (lead author of the study who sits on Advisory Board, Speakers Bureau and is consultant for or receives grants from Abbot, GSK, Janssen) and John M. Zajecka (Abbot, GSK).
Bauer, along with at least six other DBSA Advisory Board members-Charles L. Bowden (financial ties to Abbot, GSK, Janssen), Joseph Calabrese (Abbot, GSK, Janssen), Alan Gelenberg (GSK), Michael E. Thase (GSK, Janssen), Gary S Sachs (sits on Advisory Board, Speakers Bureau and is consultant for, Grants from Abbot, GSK, Janssen) and John M. Zajecka (Abbot, GSK) -conducted an $26.8 MILLION NIMH-FUNDED clinical study on the so-called Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) coordinated by Massachusetts General Hospital, to examine the course of the "disorder and the effectiveness of current treatments," including at least 7 drugs. Each of those involved in the NIMH-funded study had ties to drug companies (see above) that make the drugs studied.
MICHAEL E. THASE, MD, VICE CHAIR of the DBSA Committee: Professor of Psychiatry, University of Pittsburgh, School of Medicine and the Western Psychiatric Institute and Clinic.
Thase has directed the Depression Treatment and Research Program at Western Psychiatric Institute and Clinic since its inception in 1987 and is now the chief of adult academic psychiatry.
Member of the American College of Neuropsychopharmacology
Editor-in-chief of Psychopharmacology Bulletin.
Thase's Financial Disclosure
: Grant/Research Support: Bristol-Myers Squibb, Cyberonics, Merck, Organon, Pharmacia & Upjohn, Wyeth Ayerst Laboratories, Eli Lilly, and Sepracor
Consultant: AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Forest Pharmaceuticals, GSK, Glaxo-Wellcome Inc./CeNeRx Pharmaceuticals, Eli Lilly, Janssen, MedAvante, Inc, Merck, Neuronetics, Inc, Novartis, Organon, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, Pharmacia & Upjohn, Sepracor Inc, Shire, Supernus Pharmaceuticals, and Wyeth Ayerst
: AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GSK, Glaxo-Wellcome Inc./CeNeRx Pharmaceuticals, Organon, Parke-Davis Pharmaceuticals, Pfizer, Pharmacia & Upjohn, Sanofi-Aventis, SmithKline Beecham, Solvay, and Wyeth Ayerst Laboratories, Inc.
Owns stock in MedAvante, Inc. (a company that provides services to improve methodology and objectivity in CNS clinical trials.) Receives book royalties from American Psychiatric Publishing
, Guilford Publications
, and Herald House.Many of the studies in which Thase has been involved are with Wyeth employees.
Executive Directors and directors of this includes DBSA members, David Dunner, Alan J. Gelenberg, Mark S. Bauer, Joseph Biederman, Joseph R. Calabrese, Pedro L. Delgado, Barbara Geller, Frederick K. Goodwin Robert M. A. Hirschfeld, Wayne J. Katon, Paul E. Keck Jr., Martin B. Keller, Lauren B. Marangell, Susan L. McElroy, David J. Miklowitz, Charles B. Nemeroff, Charles O'Brien, Robert M. Post, A. John Rush Jr., Gary S. Sachs, Alan F. Schatzberg, Trisha Suppes, Michael E. Thase, Karen D. Wagner, and John M. Zajecka.
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
"Treatment-resistant depression is one of the greatest clinical challenges that psychiatrists face today, which is compounded by the fact that there is no FDA-approved medication for this illness," said Michael E. Thase, M.D., professor of psychiatry at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic.
Thase Michael E - UPMC, Pittsburgh, PA, USA
Michael E Thase, M.D. A professor of psychiatry at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic, Michael E. Thase, M.D., is an active clinical investigator whose research focuses on the assessment and treatment of mood disorders. Dr. Thase's
current research interests include differential therapeutics of major depressive disorders, long-term treatment of mood disorders and combination therapy approaches.After graduating summa cum laude from Wright State University in with a B.A. in psychology, Dr. Thase obtained his medical degree at Ohio State University in 1979.He served as an intern, resident and fellow at the Western Psychiatric Institute and Clinic before joining the University of Pittsburgh School of Medicine in 1983 as an assistant professor of psychiatry.
Since then, Dr. Thase
has fulfilled many roles at the University of Pittsburgh School of Medicine
: coordinator of outpatient studies at the Clinical Research Center for Affective Disorders; director of the Division of Mood, Anxiety, and Related Disorders; associate director of the Mental Health Clinical Research Center; associate director of the General Clinical Research Center; and director of research, Division of General Adult Psychiatry.Dr. Thase has directed the Depression Treatment and Research Program at Western Psychiatric Institute and Clinic since its inception in 1987 and is now the chief of adult academic psychiatry.A fellow of the American Psychiatric Association, Dr. Thase has received numerous honors in his field, including the Marie Eldredge Award from the American Psychiatric Association.He
is also amember of many professional and scientific societies, including the American Medical Association
, the American College of Neuropsychopharmacology
and the Society for Psychotherapy Research
has co-authored over 340 scientific articles and book chapters, as well as seven books.His
published articles are featured in various journals, including Archives
of General Psychiatry, the American Journal of Psychiatry and the British Journal of Psychiatry
.He is the editor-in-chief of Psychopharmacology Bulletin.A consultant and lecturer, Dr. Thase remains active in the community by giving numerous presentations at state hospitals regarding affective disorders.Dr. Thase
also presents seminars for community hospitals and the Office of Education and Regional Programming.
Top of Page
Media may schedule an interview with Dr. Thase
by contacting Frank Raczkiewicz.
...In the News - Michael E Thase, M.D.
...Michael E Thase, M.D.
Michael Thase, MD, ...
Michael Thase, MD, Philadelphia, Pennsylvania (1997-2017)
Bipolar Disorder Daily News Blog: October 2006 Archives
"For many patients with bipolar disorder, the depressive symptoms are significantly more debilitating and frequent than the manic symptoms, and having a medication that effectively treats both acute phases of the illness can be crucial to the overall treatment process," said Michael Thase, professor of psychiatry, University of Pittsburgh School of Medicine.